skip to primary navigationskip to content
 

PolyProx Therapeutics

last modified Mar 03, 2020 11:07 AM
PolyProx Therapeutics raises an additional £1 million seed financing from new investor, LifeArc, to validate polyproxin® drug leads in oncology...

Cambridge, UK, 02 March 2020: PolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announces that it has raised an additional £1 million seed capital from new investor, LifeArc.
The additional funding will be used to deliver in vivo proof of concept data for polyproxin® molecule leads against two oncology drug targets. This data will form the basis for Series A financing in 2021. LifeArc joins existing investors, Cambridge Innovation Capital, RT Capital and Cambridge Enterprise.
PolyProx Therapeutics is developing polyproxin® molecules that target and remove disease-causing proteins using the natural degradation machineries contained within the cell. Its initial focus is to develop polyproxin® molecule candidates for use in the treatment of cancers, targeting aberrant proteins that have previously proven difficult to target using conventional drug classes, such as small molecules or monoclonal antibodies.
A spin out from the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a decade of research and intellectual property from Founder Professor Laura Itzhaki’s laboratory. Serial Cambridge biotech entrepreneurs Kevin Moulder (Chief Operating Officer) and Andrew Sandham (Executive Chairman), lead the team.
Independent medical research charity, LifeArc, is focused on translation; helping to turn promising science into benefits for patients by advancing medical research towards patient treatments and diagnostics. LifeArc’s investment in PolyProx Therapeutics has been made via the LifeArc Seed Fund, a £25 million fund focused predominantly on opportunities in the UK with the objective ofoptimising the chances of bringing transformative science to the clinic.
Enrique Millan, Investment Principal, LifeArc Seed Fund, who will sit on the PolyProx Therapeutics board commented: “LifeArc’s Seed Fund was established to help translate promising medical research into patient benefit. We are excited to be working with the PolyProx team on the development of a novel, first-in-class therapeutic modality that could potentially address some of the challenges in cancer treatment.”
Andrew Sandham, Executive Chairman, PolyProx Therapeutics added: “We are delighted to welcome LifeArc as an investor which enables us to expand our drug discovery resources following our recent move to new laboratories in Cambridge. We have made exciting progress on our polyproxin® drug discovery projects in oncology and look forward to sharing proof of concept data with prospective investors and partners later this year.”


For more information please visit: www.polyprox.com

« April 2021 »
April
MoTuWeThFrSaSu
1234
567891011
12131415161718
19202122232425
2627282930

Proud holders of Athena SWAN Bronze

Athenaswan

RSS Feed Latest news

Designer proteins to seek and destroy

Apr 16, 2021

A new BBSRC-funded project aims to exploit de novo designed proteins to control protein-protein interactions in new ways...

Dr Matt Harris

Apr 15, 2021

Congratulations to Dr Matt Harris...

GRC Connects

Apr 08, 2021

GRC Connects: Multi-Drug Efflux Systems Efflux Pumps at the Forefront of Antibiotic Resistance and Pharmacotherapy in a Global Health Crisis...

Changes can be detected in BRCA1 breast cells before they turn cancerous

Mar 09, 2021

Researchers may have found the earliest changes that occur in seemingly healthy breast tissue long before any tumours appear, according to a new study published in Nature Communications today...

LGBTQ+ STEM Spotlight Webinar

Feb 05, 2021

In celebration of UK LGBT History month, the Pharmacology Equality and Diversity Committee & partners to host an LGBTQ+ STEM Spotlight Webinar...

View all news